By Fineline Cube 
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment and acquire equity in NanoRibo (Shanghai) Biotechnology Co., Ltd. through a three‑phase transaction that will ultimately give Kanghua full ownership of the mRNA vaccine and therapeutics developer. The first phase involves a CNY 120 million (USD 17.3 million) investment for a 27.2727% stake.
Transaction Structure & Deal Terms
| Phase | Stake Acquired | Investment Amount | Timeline |
|---|---|---|---|
| Phase 1 | 27.2727% | CNY 120 million (USD 17.3 million) | Announced |
| Phase 2 | 51% | To be disclosed | Successive |
| Phase 3 | 100% | To be disclosed | Ultimate goal |
Target Company Profile & Technology Platform
NanoRibo Bio is a Shanghai‑based biotech focused on novel mRNA‑based vaccines and therapeutics, boasting a comprehensive platform covering sequence design, delivery systems, and production processes.
Key Pipeline Asset
- RSV mRNA Vaccine: Self‑developed lyophilized formulation currently in Phase I clinical trials
- Platform Strategy: Leveraging proprietary mRNA technology to develop both preventive and therapeutic biologics targeting undruggable and hard‑to‑drug indications
Strategic Rationale & Market Impact
- Diversification: Moves Kanghua beyond IVD reagents into high‑growth mRNA therapeutics, accessing a market projected to exceed $50 billion : globally by 2030
- Platform Value: NanoRibo’s end‑to‑end capabilities reduce technology transfer risk and accelerate development timelines
- China mRNA Market: Domestic market valued at ¥15 billion : in 2025, driven by COVID‑19 vaccine success and expanding oncology applications
- Competitive Landscape: Positions Kanghua among China’s emerging mRNA players, competing with Walvax, AIM Vaccine, and Stemirna
- Revenue Synergies: Analysts estimate NanoRibo’s platform could generate ¥2–4 billion in peak sales if RSV vaccine and follow‑on pipeline succeed
Forward‑Looking Statements
This brief contains forward‑looking statements regarding transaction completion, clinical development timelines, and revenue projections for NanoRibo’s mRNA platform. Actual results may differ due to regulatory approvals, clinical trial outcomes, and competitive dynamics.-Fineline Info & Tech